Report Store Get Proposal

Home Blog Oncology 2

Oncology

medtech-news-for-spineart-ecential-robotics-zeiss

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Spineart and eCential Robotics Gain FDA Clearance for PERLA® TL Robotic Surgery Application; ZEISS CLINIC 360 Earns FDA 510(k) Clearance, Strengthening Data-Driven Patient Care; Bittium Introduces Faros Pro™ and EasyFlex™ for Extended Ambulatory ECG Monitoring; Cytrellis Expands ellacor® Micro-Coring® Technology to Australia for Full-Body Skin Resurfacing; Galmed Announces Successful First-in-Human Study of Colospan’s Novel Tissue Assessment Technology; FastWave Medical Secures FDA IDE Approval for Pivotal Artero™ Peripheral IVL Trial

Spineart and eCential Robotics Received FDA 510(k) Clearance for the PERLA® TL Application for Use with eCential® Op.n® Navigation System for Robotic Procedures On 26 August 2026, Spineart and eCential Robotics received FDA 510(k) clearance for the PERLA TL application for use with eCential Robotics’ Op.n Navigation and Robotic-Assisted Platform. The clearance extended the previously established compatibility between the PERLA platform and the Op.n navigation system to robotic-assisted workflows. The clearance enabled surgeons to integrate Spineart’s PERLA TL Open and MIS pedicle screw systems with real-time navigation and robotic assistance for both open ...

Explore More...

pharma-news-for-sobi-transthera-sciences-replimune

Sobi Partners with Innate Pharma to License Lacutamab for T-Cell Lymphoma; Yochanra Makes Global Debut in China as First Innovative Drug Designed to Overcome FGFR Inhibitor Resistance; Replimune Secures FDA Accelerated Approval for TUDRIQEV Plus Nivolumab in Advanced Cutaneous Melanoma; FDA Accepts Supplemental Biologics License Application for ENFLONSIA to Broaden RSV Indication in Young Children; Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals

medtech-news-for-rongtao-medical-nipro-lyric-health

Rongtao Medical Receives Prestigious Bonded Repair Authorization for Ultrasound in China; NIPRO Introduces ELISIO™-HX Expanded Hemodialysis System to U.S. Market Following FDA Clearance; Lyric Health Unveils Asynchronous Care Solution for Smarter, Connected Virtual Care; New England Biolab® Strengthens Cell-Free RNA Workflow with Monarch® Mag Cell-free RNA Extraction Kit; Aqua Medical Advances Type 2 Diabetes Research with First U.S. Patient Treated at UNC Health; MediView XR90™ Holographic Surgical Navigation System Debuts in Florida at Cleveland Clinic Weston Hospital

rise-of-intratumoral-cancer-therapy

Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer

pharma-news-for-astrazeneca-novartis-abbvie

EU Approves Datroway for First-Line Metastatic TNBC; FDA Broadens Pluvicto’s Reach with Approval in PSMA+ mHSPC; AbbVie Announces EU Authorization of RINVOQ for Severe Alopecia Areata; Novo Nordisk Announces Latest Developments from the ZEUS Phase III Trial; Replimune Secures Positive FDA Advisory Committee Vote for RP1 in Advanced Melanoma

protacs-treatment-landscape

PROTACs: An Emerging Drug Modality with Multiple Oncology Approvals Expected in the Coming Years

kras-inhibitors-beyond-g12c

Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C

pd-1-inhibitors-by-companies

PD-1 Inhibitors: Which Companies Are Winning the Immunotherapy Race?

liquid-biopsy-revolutionary-technique-for-cancer-diagnosis

Liquid Biopsy: The Blood Test That Is Redefining Cancer Diagnosis, Monitoring, And Precision Oncology

regenerative-medicine-revolution

The Regenerative Medicine Revolution: Opportunities Shaping the Next Decade

sanofi-sarclisa-escena-approval

Sanofi’s SARCLISA ESCENA Makes History as the First Wearable Cancer Treatment

drug-approvals-in-h2-2026

Top FDA Approvals to Watch in H2 2026: Regulatory Decisions Poised to Transform the Pharmaceutical Landscape

rise-of-targeted-therapeutics

The Rise of Targeted Therapeutics in Modern Healthcare

pharma-news-for-hengrui-kailera-gsk

Hengrui Pharma Encounters FDA Regulatory Hurdle for Camrelizumab–Rivoceranib; Kailera Therapeutics Announces Positive Results for HRS-7535/KAI-7535 Across Two Phase 3 Studies; Jemperli Underscores Durable Clinical Complete Responses in dMMR/MSI-H Rectal Cancer; FDA Approves PADCEV-Keytruda Combination for Neoadjuvant and Adjuvant Treatment of Muscle-Invasive Bladder Cancer; Sanofi’s Subcutaneous Sarclisa Escena Gains US Approval

pharma-news-for-novartis-roche-otsuka

Novartis to Acquire Myricx Bio; Roche’s Divarasib Tops Approved KRAS G12C Inhibitors in Phase III NSCLC Trial; Otsuka Reports Positive Two-Year Phase 3 Results for VOYXACT in IgA Nephropathy; Revolution Medicines Reports Early Clinical Data for Zoldonrasib Combination Regimens at ESMO GI 2026; Can-Fite Completes Patient Enrolment for Interim Analysis in Pivotal Phase 3 Psoriasis Trial

pcpg-therapeutic-landscape

Paragangliomas and Pheochromocytomas Treatment Space Steps into the Precision Therapy Era

progeria-causes-symptoms-risk-factors-and-treatment-options

Progeria Syndrome: The Rarest Case of Premature Ageing

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly